Capricor Therapeutics, a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and other rare disorders, hosted a Key Opinion Leader (KOL) call on why exosomes are uniquely suited for vaccine development on March 26, 2020.
Tagged with: Capricor Therapeutics
Mursla raises £0.5M funding to progress development of its exosome-based novel technology platform for cancer detection
17 days ago
Kimera® Labs Files First FDA Investigational New Drug (IND) Application Using Exosomes for Treatment of ARDS Secondary to COVID-19
August 20, 2020
August 13, 2020